Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial
Journal of Clinical Oncology · 2025-11 · 43 (31) · 3345-3354
DOI: 10.1200/jco.24.00936 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025-11. Verfasst von Akihiro Ohba und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity in a phase Ib trial in this population. Therefore, these three regimens were directly compared. METHODS This randomized phase II/III trial was performed at 45 centers in Japan. Eligible patients age 20-75 years with an Eastern Cooperative Oncology Group performance status of 0 or 1 and pathologically confirmed metastatic or recurrent pancreatic cancer were randomly assigned (1:1:1) to receive mFOLFIRINOX (oxaliplatin 85 mg/m 2 over 2 hours, irinotecan 150 mg/m 2 over 90 minutes, l-leucovorin 200 mg/m 2 over 2 hours, each once daily on day 1, and fluorouracil 2,400 mg/m 2 over 46 hours on days 1-3, every 2 weeks), S-IROX (oxaliplatin 85 mg/m 2 over 2 hours, irinotecan 150 mg/m 2 over 90 minutes on day 1, and S-1 80 mg/m 2 /day administered orally twice daily on days 1-7, every 2 weeks), or nab-paclitaxel (125 mg/m 2 ) + gemcitabine (1,000 mg/m 2 ) on days 1, 8, and 15 every 4 weeks. The primary end point was overall survival (OS). RESULTS A total of 527 patients were enrolled, with 426 included in the planned interim analysis. The median OS was 14.0 months (hazard ratio [HR], 1.31 [95% CI, 0.97 to 1.77]) and 13.6 months (HR, 1.35 [95% CI, 1.00 to 1.82]) in the mFOLFIRINOX and S-IROX groups, respectively, as compared with 17.1 months in the nab-paclitaxel + gemcitabine group. The predictive probability of achieving superiority in the final analysis was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- JCOG Data Center, National Cancer Center Hospital, Tokyo, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo, Japan.
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
ORCID-Profile: Akihiro Ohba, Masato Ozaka, Junki Mizusawa, Takuji Okusaka, Satoshi Kobayashi, Taro Yamashita, Masafumi Ikeda, Ichiro Yasuda, Kazuya Sugimori, Naoki Sasahira, Kenji Ikezawa, Naohiro Okano, Nobumasa Mizuno, Masayuki Furukawa, Yusuke Sano, Hiroshi Katayama, Junji Furuse, Makoto Ueno
Zitieren
APA
Ohba, A., Ozaka, M., Mizusawa, J., Okusaka, T., Kobayashi, S., Yamashita, T., Ikeda, M., Yasuda, I., Sugimori, K., Sasahira, N., Ikezawa, K., Miki, I., Okano, N., Mizuno, N., Furukawa, M., Shirakawa, H., Sano, Y., Katayama, H., Furuse, J., …, & Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG) (2025). Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial. Journal of Clinical Oncology, 43(31), 3345-3354. https://doi.org/10.1200/jco.24.00936
Vancouver
Ohba A, Ozaka M, Mizusawa J, Okusaka T, Kobayashi S, Yamashita T, et al. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial. Journal of Clinical Oncology. 2025;43(31):3345-3354. doi:10.1200/jco.24.00936
BibTeX
@article{Ohba2025,
author = {Ohba, Akihiro and Ozaka, Masato and Mizusawa, Junki and Okusaka, Takuji and Kobayashi, Satoshi and Yamashita, Taro and Ikeda, Masafumi and Yasuda, Ichiro and Sugimori, Kazuya and Sasahira, Naoki and Ikezawa, Kenji and Miki, Ikuya and Okano, Naohiro and Mizuno, Nobumasa and Furukawa, Masayuki and Shirakawa, Hirofumi and Sano, Yusuke and Katayama, Hiroshi and Furuse, Junji and Ueno, Makoto and Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG), Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG)},
title = {Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {31},
pages = {3345--3354},
doi = {10.1200/jco.24.00936}
}
EUVIMED